Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 14/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 14/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 14/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 12/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.83 |
| ▸ | PDE2A | O00408 | 1/20 | 0.66 |
| ▸ | PDE5A | O76074 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CFTR | P13569 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | SCN1A | P35498 | 1/20 | 0.66 |
| ▸ | PDE6C | P51160 | 1/20 | 0.66 |
| ▸ | PDE1A | P54750 | 1/20 | 0.66 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.66 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177911 | 0.96 | PDE4A (0.92) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381254 | 0.94 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3186630 | 0.91 | PDE4A (0.94) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9765669 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11361392 | 0.90 | PDE4A (0.91) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3842077 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381259 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381240 | 0.88 | ADORA2B (0.94) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3190853 | 0.88 | ADORA2B (0.92) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7109948 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | claimed |
| US-4288433-A | THIOETHER AND A XANTHINE DERIVATIVE | L'OREAL (FR) | 1981-09-08 | — | — | US | claimed |
| EP-4277628-A1 | TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME | Active Biotech AB (SE) | 2023-11-22 | — | — | EP | disclosed |
| EP-2671539-B1 | TRANSPLANT GUIDING PART AND TRANSPLANT TOOL | CYFUSE BIOMEDICAL KK (JP) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022152902-A1 | TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME | ACTIVE BIOTECH AB (SE) | 2022-07-21 | — | — | WO | disclosed |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
| US-9469833-B2 | Transplantation guide and transplantation device | Cyfuse Biomedical K. K. (JP) | 2016-10-18 | — | — | US | disclosed |
| EP-1497444-B1 | METHODS FOR INCREASING POLYPEPTIDE PRODUCTION | IMMUNEX CORP (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20140283356-A1 | DEVICE FOR MANUFACTURING SUPPORTING BODY FOR PRODUCTION OF THREE-DIMENSIONAL STRUCTURE OF CELLS | SAGA UNIVERSITY (JP) | 2014-09-25 | — | — | US | disclosed |
| US-6872549-B2 | Methods for increasing polypeptide production | IMMUNEX CORPORATION (US) | 2005-03-29 | — | — | US | disclosed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20030211579-A1 | Methods for increasing polypeptide production | IMMUNEX CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | disclosed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | disclosed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | disclosed |
| US-4288433-A | THIOETHER AND A XANTHINE DERIVATIVE | L'OREAL (FR) | 1981-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | PDE4A 1873/4885PDE4B 1806/4885PDE4C 2442/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | PDE4A 1873/4885PDE4B 1806/4885PDE4C 2442/4885 |
| US-20030211579-A1 | Methods for increasing polypeptide production | IAPP, NPEPPS, ANPEP | PDE4A 669/4885PDE4B 785/4885PDE4C 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.